Urology Annals
About UA | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionLogin 
Urology Annals
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 7   Home Print this page  Email this page Small font size Default font size Increase font size


 
Table of Contents
CASE REPORT
Year : 2013  |  Volume : 5  |  Issue : 3  |  Page : 212-214  

Holmium:YAG laser ablation of upper urinary tract transitional cell carcinoma with new Olympus digital flexible ureteroscope


Department of Urology, Hospital del Henares, Coslada, Madrid, Spain

Date of Submission13-Oct-2011
Date of Acceptance03-Mar-2012
Date of Web Publication29-Jul-2013

Correspondence Address:
Pablo Garrido Abad
Calle Arcos de la Frontera 27, 2°A, 28023, Madrid
Spain
Login to access the Email id


DOI: 10.4103/0974-7796.115748

PMID: 24049390

Get Permissions

   Abstract 

Upper urinary tract transitional (UUTT) cell carcinoma is a relatively uncommon urologic tumor. The traditional treatment approach for them is radical nephroureterectomy. However, in recent years, less-invasive treatments, including different nephron-sparing procedures, have become increasingly popular. We report a case of laser ablation of UUTT cell carcinoma using new Olympus digital flexible ureteroscope (URF-V).

Keywords: Holmium:YAG laser, upper tract urothelial carcinoma, ureteroscope


How to cite this article:
Abad PG, del Peso AC, Arjona MF. Holmium:YAG laser ablation of upper urinary tract transitional cell carcinoma with new Olympus digital flexible ureteroscope. Urol Ann 2013;5:212-4

How to cite this URL:
Abad PG, del Peso AC, Arjona MF. Holmium:YAG laser ablation of upper urinary tract transitional cell carcinoma with new Olympus digital flexible ureteroscope. Urol Ann [serial online] 2013 [cited 2014 Apr 23];5:212-4. Available from: http://www.urologyannals.com/text.asp?2013/5/3/212/115748


   Introduction Top


Nephroureterectomy with bladder-cugg removal is still the standard treatment for UUTT because of the high recurrence rates in the remaining distal ureter, the multi-centricity on the same side, and the low incidence of bilateral tumours. In order to preserve renal function, therapeutic approaches have evolved from complex open surgery to minimally invasive ureteroscopic therapy in selected cases. [1]

This option has been greatly facilitated by the modern development of fine-bore, actively deflectable ureteroscopes in addition to ablative and coagulative laser technologies. [2]


   Case Report Top


A 62-year-old male with a history of tuberculosis and left nephroureterectomy in 1992 because mastic kidney was admitted to our hospital presenting repeated microscopically haematuria.

Initially, IVU and CT were performed, without conclusive findings in the collecting system. Due to higher resolution image and diagnostic ability, endoscopy is commonly used to diagnose upper urinary tract tumors by our group in selected cases. Then, using an access sheath 12/14 Flexor TM (Cook) and with the help of a hydrophilic guide wire (Terumo 0.035"), we performed a flexible ureteroscopy, revealing a small papillary tumor in the right kidney middle calyx. A biopsy of the tumor was obtained by 2.4 Fr tipless nitinol basket. The result of the biopsy was a low-grade urothelial tumor. Cytology was negative.

After discussion regarding ureteroscopic treatment of this lesion, including the theoretical risk of tumor recurrences we decided ureteroscopic management of the tumor using Holmium:YAG laser ablation.

A new 8.5 F Olympus ® digital ureteroscope (ODF-URS): URF-V was used to locate the urothelial tumor [Figure 1] and ablation of the tumor was performed by 200 μm laser Stone Light 15 W Ho: YAG fiber [Figure 2] and [Figure 3] set at 1.0 J and 10 Hz.
Figure 1: High quality endoscopic image from callyceal tumor with new Olympus digital flexible ureteroscope (URF-V)

Click here to view
Figure 2: Tumor ablation with 200 μm Ho:YAG laser fiber

Click here to view
Figure 3: Complete ablation of the callyceal tumor

Click here to view


The procedure was completed in 30 min, and the estimated blood loss was less than 50 mL. A Foley catheter was placed after surgery up to 12 h.

Patient hospital stay was 24 h without any post-operative complication. The patient has been followed for 6 months without evidence of recurrence on surveilance ureteroscopy, cytology, cystoscopy or IVU.


   Discussion Top


Ureteroscopy makes you to visualize the tumour directly to improve the diagnosis accuracy for upper tract lesions compared with that of the conventional evaluation with imaging and urinary cytology.

UUTT cell carcinoma is a relatively uncommon urologic tumor accounting for 5-6% of all urothelial malignancy and 5-10% of all renal cancers. Ureteral tumors occur in about 25% of UUTT cases; most occur in the distal ureter (70%), followed by the middle ureter (25%) and the remainder occur in the proximal ureter. Bilateral disease is rare and occurs in 2-4% of cases. A bladder lesion develops in 30-75% of patients with UUTT. [1]

Based on the established endoscopic treatment of bladder tumors, the application of endoscopic techniques became limited only by the instrumentation available. This concept became a reality as appropriate ureteroscopes became available.

The first instruments used for endoscopic antegrade resection of the UUTT were electric coagulators but the energy needed for resection was high and they could cause stricture or perforation. With the development of progressively smaller and more durable rigid and flexible ureteroscopes, retrograde endoscopic procedures have become more practical and effective, furthered by the use of different lasers (Ho:YAG and Neodimium:YAG [Nd:YAG]). Ho:YAG laser can evaporate, coagulate, and resect tumors. Can be used safely since its radiation affects only surface (<0.4 mm). [3],[4] The Nd:YAG laser is better for larger areas of tumor ablation (> 2cm), but it is more dangerous tool, with a greater potential for renal pelvic and ureteric perforation than the Ho:YAG laser. [5]

Majority of this surgical procedures performed with flexible devices have the technical drawback of a poor optic image provided by fiberoptic endoscope. New 8.5 Fr Olympus ® digital flexible ureteroscope (ODF-URS): URF-V with EndoEYE technology (CCD camera located at the distal tip of the endoscope) allows for focus-free high quality imaging. ODF-URS: URF-V is compatible with Ho: YAG laser for treatment within the kidney through 3.6 Fr working channel, allowing for clear image capture without any image distortion during treatment, 180° and 275° (up/down) optimal deflection for easy access to all areas of the kidney and Olympus' exclusive insertion tube rotation function allows the user to make fine manipulations of the endoscope tip while keeping the control hand in a neutral position. This could potentially reduce user fatigue due to excessive hand movement.

The indications for endoscopic treatment for UUTT are not yet well defined. Patients for whom endoscopic tumour ablation is indicated include those with a solitary kidney, renal insuffiency, bilateral UC of the upper urinary tract, or those with a high risk of medical complication associated with poor operative risk. [6]

Elliot et al. used the following selection criteria for definitive endoscopic treatment of UUTT: (a) Normal contralateral kidney was present, (b) All lesions were papillary and superficial in appearance, (c) Complete visualisation was possible, (d) Complete resection was possible, (e) Lesion was <2 cm in diameter, (f) There was no computed tomographic evidence of parenchymal invasion and (g) Patient was responsible and deemed capable of adhering to a strict schedule of follow-up evaluations. [7]

Recurrence rates are reported in 9.5-45% of cases. The mechanism of recurrence has not been elucidated, but multifocal recurrence, where the source of tumor development remains, is believed to be the cause. High-grade tumors and pre-operative urinary cytology-positive cases are more likely to have recurrence. [3]

Careful, lifelong follow-up is mandatory after endoscopic treatment of all UUTT cell carcinomas.

A well-established surveillance schedule was presented by Ho and Chow, consisting of cystoscopy and cytology every 3 months alternating with cystoscopy, retrograde pyelogram, cytology, and flexible ureteroscopy every 6 mo. for the first 2 years, then cystoscopy every 6 months, and annually ureteroscopy. [8]

Transurethral endoscopy with the Ho:YAG laser, as nephron-sparing surgery for UUTT is safe and effective during a long period of observation. Good long-term results can be expected in elective cases if the indications are carefully selected. The initial stage and grade of the tumor is the key to defining the ultimate success of treatment. [1],[3]

However, there are still significant limitations to ureteroscopic treatment, such as inadequate staging, possible risks of local recurrence and the possibility of causing tumour progression after endoscopic treatment.

 
   References Top

1.Bader MJ, Sroka R, Gratzke C, Seitz M, Weidlich P, Staehler M, et al. Laser therapy for upper urinary tract transitional cell carcinoma: Indications and management. Eur Urol 2009;56:65-71.  Back to cited text no. 1
    
2.Painter DJ, Denton K, Timoney AG, Keeley FX. Ureteroscopic management of upper-tract urothelial cancer: An exciting nephron-sparing option or an unacceptable risk? J Endourol 2008;22:1237-9.  Back to cited text no. 2
[PUBMED]    
3.Yamada Y, Inoue Y, Nakamura K, Naruse K, Aoki S, Taki T, et al. Long-term results and management of ureteral transitional cell carcinoma using the holmium:YAG laser via rigid-ureteroscopy. Oncol Rep 2009;21:345-9.  Back to cited text no. 3
[PUBMED]    
4.Johnson GB, Grasso M. Ureteroscopic management of upper urinary tract transitional cell carcinoma. Curr Opin Urol 2005;15:89-93.  Back to cited text no. 4
[PUBMED]    
5.Tada Y, Yokomizo A, Koga H, Seki N, Kuroiwa K, Tatsugami K, et al. BJUI; 2010:362-6.  Back to cited text no. 5
    
6.Krambeck AE, Thompson RH, Lohse CM et al. Imperative indications for conservative management of upper tract transitional cell carcinoma. J Urol 2007;178:792-7.  Back to cited text no. 6
    
7.Elliot DS, Segura JW, Lightner D, Patterson DE, Blute ML. Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney. Urology 2001;58:174-8.  Back to cited text no. 7
    
8.Ho KL, Chow GK. Ureteroscopic resection of upper-tract transitional cell carcinoma. J Endourol 2005;19:841-7.  Back to cited text no. 8
[PUBMED]    


    Figures

  [Figure 1], [Figure 2], [Figure 3]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   Case Report
   Discussion
    References
    Article Figures

 Article Access Statistics
    Viewed372    
    Printed17    
    Emailed0    
    PDF Downloaded51    
    Comments [Add]    

Recommend this journal